OncoMatch/Clinical Trials/NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Is NCT06692738 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Rilvegostomig · Pembrolizumab · Carboplatin · Paclitaxel · Nab-paclitaxel — The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression TC ≥ 1% (TC ≥ 1%)
Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%.
Disease stage
Required: Stage IV
Metastatic disease required
Prior therapy
Cannot have received: systemic therapy
Any prior systemic therapy received for advanced or mNSCLC.
Cannot have received: anti-PD-1 therapy
Any prior treatment with an anti-PD-1 or anti-PD-L1 agent.
Cannot have received: anti-TIGIT therapy
Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.
Cannot have received: anticancer therapy targeting immune-regulatory receptors or mechanisms
Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms.
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Covington, Louisiana
- Research Site · Shreveport, Louisiana
- Research Site · Shreveport, Louisiana
- Research Site · South Portland, Maine
- Research Site · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06692738 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 expression TC ≥ 1% is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify